Free tool
Oncology stocks
We cover 5 companies grouped under the Oncology theme. The median market value in the group is $20.65B. Across the group, the median move over the past trading day is +0.14%. Price change over the past year runs from −16.4% to +118.7% across the middle 80 percent of the group, with a median of +53.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% | Oct 29, 2026 |
| 0J9P.L | Incyte Corporation | $21.10B | Large cap | +53.49% | Oct 27, 2026 |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% | Nov 5, 2026 |
| 0LOV.L | Verastem, Inc. | $470.33M | Small cap | −19.93% | Nov 3, 2026 |
| 0XOD.L | UroGen Pharma Ltd. | $347.24M | Small cap | +136.88% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.